THE US Food and Drug
Administration’s (FDA’s) Generating
Antibiotics Incentives Now (GAIN)
Act is gaining traction in its objective
to incentivise the development of
new antibiotics.
Under the GAIN act, certain
antibacterial or antifungal drugs
intended to treat serious or lifethreatening
infections can be
designated “Qualified Infectious
Disease Products” (QIDPs) which
gives them fast track designation for
priority review as well as potentially
receiving up to five years additional
marketing exclusivity, free of generic
competition.
To date, the FDA has granted 52
QIDP designations to 35 different
unique molecules.
To read more, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.